NeoDynamics AB (publ) announced the initiation of their first NeoNavia order from a prominent US university hospital specializing in the treatment of breast cancer. However modest in size, the order will serve as an important reference as the commercial rollout continues to garner interest and acceptance at both academic and community based breast centers throughout the U.S. This milestone further demonstrates the commercial viability of the innovative pulse technology, and its role in shifting the paradigm in the diagnosis of breast cancer, which is in line with what has been communicated. The company commercially launched NeoNavia in the US at two prestigious conferences in the 2nd quarter of 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.998 SEK | -0.20% | -0.20% | -54.64% |
25/04 | NeoDynamics AB Announces CFO Changes | CI |
15/04 | Air Astana Partner with Italy-based Neos | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-54.64% | 3.05M | |
-15.52% | 19.69B | |
-39.00% | 3.01B | |
+22.02% | 1.94B | |
-0.62% | 1.66B | |
+35.83% | 1.34B | |
-22.01% | 895M | |
+6.26% | 827M | |
-23.80% | 638M | |
+10.38% | 516M |
- Stock Market
- Equities
- NEOD Stock
- News NEOS AB
- NeoDynamics AB Receives First Commercial Order from Top University Hospital